Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors.

abstract：BACKGROUND:Uniportal video-assisted thoracoscopic surgery (VATS) is being more widely used in lung cancer, yet reports on its application in pneumonectomies are limited. This study aimed to evaluate the safety and feasibility of uniportal video-assisted thoracoscopic left pneumonectomy for lung cancer. METHODS:A serie...

journal_title：Thoracic cancer

authors： Li J,Xue Q,Gao Y,Mao Y,Zhao J,Gao S

更新日期：2021-01-06 00:00:00

abstract：:Immunoglobulin light-chain (AL) amyloidosis is a monoclonal plasma cell neoplasm that has a tendency to bleed easily. However, the potential risks of transbronchial biopsy in such cases have not been fully proven. Here, we report a case of parotid and intrathoracic AL amyloid tumors that presented as endobronchial pro...

journal_title：Thoracic cancer

authors： Tomono H,Soda H,Fukuda Y,Tanaka Y,Ono S,Shimada M,Iwasaki K,Hisanaga M,Yamaguchi H,Mukae H

更新日期：2019-10-01 00:00:00

abstract：BACKGROUND:The abundance of tumor infiltrating CD8 T cells is an important parameter for antitumor effect of PD-1/PD-L1 immune checkpoint inhibitors, which is less in epidermal growth factor receptor (EGFR) mutation than wild-type non-small cell lung cancer (NSCLC). The mechanism still requires further study. METHODS:...

journal_title：Thoracic cancer

authors： Zhao C,Su C,Li X,Zhou C

更新日期：2020-08-01 00:00:00

abstract：BACKGROUND:Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life-threatening adverse event. The purpose of this study was to evaluate whether the development of immune-related adverse events (irAEs), especially ILD, was associated with treatment efficacy and to research th...

journal_title：Thoracic cancer

authors： Sugano T,Seike M,Saito Y,Kashiwada T,Terasaki Y,Takano N,Hisakane K,Takahashi S,Tanaka T,Takeuchi S,Miyanaga A,Minegishi Y,Noro R,Kubota K,Gemma A

更新日期：2020-04-01 00:00:00

abstract：:Several authors have previously reported that patients with pulmonary combined large cell neuroendocrine cancer ( LCNEC) have a poor prognosis and there is no consensus on the treatment strategy for combined LCNEC as well as LCNEC. Here, we report the case of a long-term survivor with pulmonary combined LCNEC. The pat...

journal_title：Thoracic cancer

authors： Oda R,Okuda K,Yamashita Y,Sakane T,Tatematsu T,Yokota K,Endo K,Nakanishi R

更新日期：2020-07-01 00:00:00

abstract：BACKGROUND:The aim of this study was to report a single referral center experience in robotic extended thymectomy for clinical early stage thymomas, evaluating its safety, feasibility and efficacy, with special regard to oncological outcomes. METHODS:Between January 2009 and December 2012, we retrospectively selected ...

journal_title：Thoracic cancer

authors： Huang P,Ye B,Yang Y,Tantai JC,Zhao H

更新日期：2014-07-01 00:00:00

abstract：BACKGROUND:Metastatic or recurrent thyroid cancer often behaves aggressively, and approximately two-thirds of patients present with radioiodine resistance. Effective therapies to suppress thyroid cancer metastasis are urgently needed. Nevirapine has been proved to suppress tumor growth and induce differentiation in sev...

journal_title：Thoracic cancer

authors： Shang H,Zhao J,Yao J,Wang H,Wang S,Dong J,Liao L

更新日期：2019-12-01 00:00:00

abstract：BACKGROUND:Plasmid construction of small fragments of interest (such as insertion of small fragment marker genes, expression of shRNA, siRNA, etc) is the basis of many biomolecular experiments. Here, we describe a method to clone short DNA into vectors by polymerase chain reaction (PCR), named one-step PCR cloning. Our...

journal_title：Thoracic cancer

authors： Tao CC,Yang Y,Li F,Qiao L,Wu Y,Sun XD,Zhang YY,Li CL

更新日期：2020-11-01 00:00:00

abstract：:This report describes the surgical management of a male patient with early-stage lung cancer who underwent thoracoscopic completion right lower lobectomy after previously undergoing sublobar resection for multifocal ground glass nodules of the lung. Perioperative considerations associated with the management of dense ...

journal_title：Thoracic cancer

authors： Liu YW,Chou SH,Hung JY,Kao CN,Chang PC

更新日期：2019-05-01 00:00:00

abstract：:ROS1 rearrangement is a validated therapeutic driver gene in non-small cell lung cancer (NSCLC) and represents a small subset (1-2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi-targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib has demonstrated re...

journal_title：Thoracic cancer

authors： Zhu YC,Zhou YF,Wang WX,Xu CW,Zhuang W,Du KQ,Chen G

更新日期：2018-05-01 00:00:00

abstract：BACKGROUND:The study was conducted to compare the clinicopathological characteristics, survival outcomes, and metastatic patterns between pulmonary large cell neuroendocrine carcinoma (LCNEC) and other non-small cell lung cancer (ONSCLC), and to identify the prognostic factors of LCNEC. METHODS:Data of patients diagno...

journal_title：Thoracic cancer

authors： Yang Q,Xu Z,Chen X,Zheng L,Yu Y,Zhao X,Chen M,Luo B,Wang J,Sun J

更新日期：2019-04-01 00:00:00

abstract：BACKGROUND:Advanced non-small cell lung cancer (NSCLC) has a high mortality rate and poor prognosis. However, outcomes have gradually improved after the introduction of novel immunotherapies, including immune checkpoint inhibitors (ICIs). Although programmed death-ligand 1 (PD-L1) expression in tumor tissues is a known...

journal_title：Thoracic cancer

authors： Katakura S,Kobayashi N,Hashimoto H,Kamimaki C,Tanaka K,Kubo S,Nakashima K,Teranishi S,Manabe S,Watanabe K,Horita N,Hara Y,Yamamoto M,Kudo M,Piao H,Kaneko T

更新日期：2020-10-01 00:00:00

abstract：BACKGROUND:Approximately 15% of lung cancer patients are diagnosed in early stages. Microscopic proof of disease cannot always be obtained because of comorbidity or reluctance to undergo invasive diagnostic procedures. In the current study, survival data of patients with and without pathology are compared. METHODS:One...

journal_title：Thoracic cancer

authors： Zehentmayr F,Sprenger M,Rettenbacher L,Wass R,Porsch P,Fastner G,Pirich C,Studnicka M,Sedlmayer F

更新日期：2019-02-01 00:00:00

abstract：:The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large-cell lymphoma. Since then, ...

journal_title：Thoracic cancer

authors： Du X,Shao Y,Qin HF,Tai YH,Gao HJ

更新日期：2018-04-01 00:00:00

abstract：BACKGROUND:Malignant pleural mesothelioma (MPM) is an aggressive cancer refractory to current therapies. Reduced expression of micro ribonucleic acid (miR)-591 in a range of cancer types has suggested it is a potent tumor suppressor, and overexpression has been shown to inhibit tumor cell growth. The role of miR-591 in...

journal_title：Thoracic cancer

authors： Cheng S,Xu Y,Shi Z,Lin Y,Hoang CD,Zhang X

更新日期：2016-04-26 00:00:00

abstract：:Almost all epidermal growth factor receptor (EGFR)-mutant lung cancers develop resistance to EGFR-tyrosine kinase inhibitors. Several mechanisms for this acquired resistance have been identified, including development of an EGFR T790M mutation, MET amplification, hepatocyte growth factor overexpression, loss of phosph...

journal_title：Thoracic cancer

authors： Xu S,Liu X,Liu R,Shi T,Li X,Zhong D,Wang Y,Chen G,Chen J

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:The aim of this study was to investigate the patterns and influencing factors of local-regional recurrence of lower thoracic esophageal squamous cell carcinoma (TESCC) after curative resection and to delineate the clinical target volume (CTV) of postoperative radiotherapy (PORT). METHODS:From January 2009 t...

journal_title：Thoracic cancer

authors： Liu J,Cai X,Liu Q,Li H,Cheng Y,Fu X

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:This study aimed to compare survival between standard lobectomy and surgeons' preference sublobar resection among patients with stage I non-small cell lung cancer (NSCLC). METHODS:Medical records of patients undergoing pulmonary resection between 2006 and 2016 were reviewed retrospectively. Differences in d...

journal_title：Thoracic cancer

authors： Huang CS,Hsu PK,Chen CK,Yeh YC,Hsu HS,Shih CC,Huang BS

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:Eugenol, a natural compound available in Syzigium aromaticum (cloves), is exploited for various medicinal applications. Eugenol induces apoptosis and functions as an anti-cancer drug in several types of tumors. We investigated the tumor suppressive role and potential mechanisms of eugenol in human lung cance...

journal_title：Thoracic cancer

authors： Fangjun L,Zhijia Y

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Connective tissue disease increases the risk of lung cancer, but whether rheumatoid arthritis (RA) has an effect on the overall survival (OS) rate in this population has not been well studied. METHODS:Patients diagnosed with lung cancer between January 2015 and December 2017 were enrolled in this retrospect...

journal_title：Thoracic cancer

authors： Zhang L,Zhao Q,Yuan F,Liu M

更新日期：2020-06-01 00:00:00

abstract：:Tyrosine kinase inhibitors are used as first-line treatment for non-small cell lung cancer (NSCLC) patients harboring driver mutations in EGFR, ALK, ROS1, and BRAF. Currently, standard molecular testing approaches help identify single genes for such targetable driver mutations in NSCLC; however, next-generation sequen...

journal_title：Thoracic cancer

authors： Onozawa H,Saito H,Sunami K,Kubo T,Yamamoto N,Kasajima R,Ohtsu T,Hiroshima Y,Kanamori H,Yokose T,Miyagi Y

更新日期：2020-12-01 00:00:00

abstract：BACKGROUND:Lung cancer is the leading cause of cancer-related deaths. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective for advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations, some patients experience little or no response. The Glasgow prognostic score (GPS...

journal_title：Thoracic cancer

authors： Kasahara N,Imai H,Naruse I,Tsukagoshi Y,Kotake M,Sunaga N,Kaira K,Maeno T,Asao T,Hisada T

更新日期：2020-08-01 00:00:00

abstract：BACKGROUND:The number of patients diagnosed with early stage disease (T1a or T1b) has been increasing. This study was conducted to investigate the effect of esophagectomy (ES), endoscopic therapy (ET), and radiotherapy (RT) on long-term survival in elderly patients with cT1N0M0 esophageal cancer. METHODS:We searched t...

journal_title：Thoracic cancer

authors： Qin J,Peng Y,Chen W,Ma H,Zheng Y,Li Y,Wang J

更新日期：2019-07-01 00:00:00

abstract：:The role of Chlamydia pneumoniae in the cause of lung cancer is controversial. In this study, we investigated the association between C. pneumoniae immunoglobulin (Ig) G antibodies and risk of lung cancer among non-smoking women. C. pneumoniae IgG antibody levels were compared between 192 adult Chinese women who met t...

journal_title：Thoracic cancer

authors： Liu Z,Su M,Yu SC,Yin ZH,Zhou BS

更新日期：2010-09-01 00:00:00

abstract：BACKGROUND:This study investigated the correlations between CXCR4 and VEGF-C expression and lymph node metastasis in non-small cell lung cancer (NSCLC). METHODS:Tumor specimens, lymph nodes, and normal lung tissues were obtained from 110 NSCLC patients who underwent complete resection. Quantitative reverse transcripti...

journal_title：Thoracic cancer

authors： Bi MM,Shang B,Wang Z,Chen G

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:The prognostic values of preoperative neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), and platelet/lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) have been previously described. This study assessed the prognostic values of other pretreatment complete blood cell parameters in...

journal_title：Thoracic cancer

authors： Yuan C,Li N,Mao X,Liu Z,Ou W,Wang SY

更新日期：2017-07-01 00:00:00

abstract：BACKGROUND:The standard of care for fit locally advanced non-small cell lung cancer (NSCLC) patients is concurrent chemoradiotherapy (CCRT). However, in a subset of patients with lung adenocarcinoma with mutant EGFR (LA-mEGFR), the role of EGFR-tyrosine kinase inhibitors (TKIs) is not clear. We compared CCRT versus TKI...

journal_title：Thoracic cancer

authors： Hsia TC,Liang JA,Li CC,Chien CR

更新日期：2018-11-01 00:00:00

abstract：:Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used in patients with EGFR-mutant lung cancer. Meanwhile, thermal ablation such as microwave ablation has been an option for selected patients. Herein, we describe three cases of pneumothorax that occurred in microwave ablation (MWA) ...

journal_title：Thoracic cancer

authors： Guo R,Li Y,Bie Z,Li B,Li X

更新日期：2020-07-01 00:00:00

abstract：BACKGROUND:MicroRNA-128 (miR-128) serves as a regulator by inducing cancer cell apoptosis, differentiation, the epithelial-to-mesenchymal transition process, and tumor growth by mediating different targets. NIMA-related kinase 2 (NEK2) is aberrantly expressed in lung cancer. The miR-128/NEK2 pathway has been reported t...

journal_title：Thoracic cancer

authors： Zhao D,Han W,Liu X,Cui D,Chen Y

更新日期：2017-07-01 00:00:00

abstract：BACKGROUND:  The optimal strategy was not established for patients who initially responded to gefitinib although re-administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been proven to be an option. Gefitinib and erlotinib were compared as salvage treatment after gefitinib fail...

journal_title：Thoracic cancer

authors： Yu S,Wang Y,Li J,Hao X,Wang B,Wang Z,Zhang X,Shi Y

更新日期：2013-05-01 00:00:00